Assessing Reports of Therapeutic Trials

Lionel, N. D. W.; Herxheimer, A.
September 1970
British Medical Journal;9/12/1970, Vol. 3 Issue 5723, p637
Academic Journal
No abstract available.


Related Articles

  • Practical clinical pharmacology. Therapeutic drug monitoring and clinical trials. Brodie, Martin J.; Feely, John // British Medical Journal (Clinical Research Edition);4/16/1988, Vol. 296 Issue 6629, p1110 

    Focuses on therapeutic drug monitoring and clinical trials. Use of measured concentration in determining maximum optimum dose of a drug; Elimination half life of carbamazepine; Importance of assessing the protocols or reports of trials.

  • The number needed to treat: A clinically useful nomogram in its proper context. Chatellier, Gilles; Zapletal, Eric // BMJ: British Medical Journal (International Edition);2/17/96, Vol. 312 Issue 7028, p426 

    Reports on the development of a nomogram to calculate the number needed to treat in a clinical trial. Expression of the benefit of an active treatment over a control; Use for summarizing the results of a therapeutic trial; Assessment of the value of several interventions.

  • Trials assesses new contact dermatitis tx.  // Dermatology Times;Dec95, Vol. 16 Issue 12, p4 

    Reports on the beginning of a Phase I/II trail to assess the potential of a cysteine prodrug (procysteine) for the treatment of contact dermatitis by Transcend Therapeutics Incorporated. What trial is designed to replenish; Rationale for testing.

  • SPA in Hand, Onconova Moves Estybon to Phase III.  // Bioworld Week;10/11/2010, Vol. 18 Issue 41, p3 

    The article reports on the agreement reached by Onconova Therapeutics Inc. and the U.S. Food and Drug Administration (FDA) on a special protocol assessment (SPA) for the Phase III trial of Estybon.

  • Transition Therapeutics completes enrollment for trial of interferon enhancing therapy.  // PharmaWatch: CNS;July 2003, Vol. 2 Issue 7, p19 

    Reports on the completion of the clinical trial of the interferon enhancer EMZ701 conducted by Transition Therapeutics Inc. in the U.S. Assessment on the side effects of the drugs; Use of the drugs during the treatment of the patients with multiple sclerosis; Availability of the products.

  • Auven shows positive results of Seciera for dry eye.  // Optometry Times;Dec2015, Vol. 7 Issue 12, p17 

    The article reports that Auven Therapeutics has announced positive results of its Phase 2b/3 clinical trial that assess the safety and efficacy of its patented nanomicellar formulation of cyclosporine drug Seciera as of December 2015.

  • Adequacy of Published Oncology Randomized Controlled Trials to Provide Therapeutic Details Needed for Clinical Application. Duff, Jennifer M.; Leather, Helen; Walden, Edmund O.; LaPlant, Kourtney D.; George Jr., Thomas J. // JNCI: Journal of the National Cancer Institute;5/19/2010, Vol. 102 Issue 10, p702 

    Background: Randomized controlled trials (RCTs) improve clinical care through evidence-based results. Guidelines exist for RCT result reporting, but specific details of therapeutic administration promote clinical application and reproduction of the trial design. We assess the reporting...

  • NIH begins phase II study of Guilford's GPI 1485 compound for Parkinson's disease.  // PharmaWatch: CNS;April 2004, Vol. 3 Issue 4, p8 

    Reports on the confirmation of the U.S. National Institutes of Health in initiating a clinical trial to test the neuroimmunophilin ligand from Guilford Pharmaceuticals Inc. Efforts of the institute to investigate novel neuroprotective therapies for Parkinson's disease; Basis of the selection of...

  • Delex begins phase II AeroLEF trial measuring the drug's efficacy for post-surgical pain.  // PharmaWatch: CNS;April 2004, Vol. 3 Issue 4, p13 

    Reports on the commencement of the clinical trial for AeroLEF by Delex Therapeutics Inc. in Nova Scotia. Usefulness of the aerosolized liposome encapsulated Fentanyl in treating postoperative pain; Assessment of the analgesic effects of the drug and its delivery system; Intention of the company...

  • Pain Therapeutics begins enrollment of patients for Oxytrex phase III trial.  // PharmaWatch: CNS;April 2004, Vol. 3 Issue 4, p13 

    Reports on the enrolment of patients for the clinical trial of the oral painkiller, Oxytrex, by Pain Therapeutics Inc. Use of the drug in treating patients who suffer from sever chronic pain; Detection of the ability of the painkiller to inhibit an excitatory effect of opioid receptors; Design...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics